...
机译:模型知识药物发育在儿科药物开发,监管评价和标签中的作用
US FDA 10903 New Hampshire Ave Silver Spring MD 20993 USA;
US FDA 10903 New Hampshire Ave Silver Spring MD 20993 USA;
US FDA 10903 New Hampshire Ave Silver Spring MD 20993 USA;
US FDA 10903 New Hampshire Ave Silver Spring MD 20993 USA;
US FDA 10903 New Hampshire Ave Silver Spring MD 20993 USA;
US FDA 10903 New Hampshire Ave Silver Spring MD 20993 USA;
US FDA 10903 New Hampshire Ave Silver Spring MD 20993 USA;
US FDA 10903 New Hampshire Ave Silver Spring MD 20993 USA;
US FDA 10903 New Hampshire Ave Silver Spring MD 20993 USA;
US FDA 10903 New Hampshire Ave Silver Spring MD 20993 USA;
US FDA 10903 New Hampshire Ave Silver Spring MD 20993 USA;
US FDA 10903 New Hampshire Ave Silver Spring MD 20993 USA;
US FDA 10903 New Hampshire Ave Silver Spring MD 20993 USA;
US FDA 10903 New Hampshire Ave Silver Spring MD 20993 USA;
US FDA 10903 New Hampshire Ave Silver Spring MD 20993 USA;
dose selection and optimization; informing clinical trial design; leveraging knowledge; model-informed drug development; pediatric drug development; pediatric ontogeny;
机译:模型知识药物发育在儿科药物开发,监管评价和标签中的作用
机译:模型知识的药物开发:当前美国监管实践和未来的考虑
机译:模型知识的药物开发:关于进展的监管视角
机译:质谱法在抗体药物缀合物药物发育中的作用:曲妥珠单抗(T-DM1)
机译:逆逆药物和处方药:2015-2019财政年度的警告信的监管数据库和数据分析的发展
机译:使用四十年的FDA孤儿药物指标来描述稀有疾病药物发展的趋势:在稀有肿瘤神经系统和儿科发病疾病的毒药的发展中看到的大量增长
机译:模型知识药物发育在儿科药物开发,监管评估和标签中的作用
机译:新药开发:科学,商业,监管和知识产权问题被列为妨碍药物开发的努力